Stock Track | Twist Bioscience Soars 19% on Stellar Q4 Earnings Beat and Upbeat Guidance

Stock Track11-18

Shares of Twist Bioscience (TWST) skyrocketed 19.27% in the pre-market session on Monday, following the company's impressive fiscal fourth quarter 2024 results that surpassed analyst estimates. The synthetic biology company's strong performance was fueled by robust demand for its synthetic DNA products and services across various industries.

For the fourth quarter, Twist Bioscience reported revenue of $84.7 million, a 26.5% increase from the prior year and topping consensus estimates of $82.2 million. The company's net loss narrowed to $0.59 per share, significantly better than the expected loss of $0.71 per share.

Additionally, Twist Bioscience provided an optimistic outlook for fiscal 2025, forecasting full-year revenue between $367 million and $377 million, exceeding analysts' projections of $371.4 million. The company's proprietary DNA synthesis platform continues to gain momentum, positioning Twist Bioscience as a leader in the rapidly growing synthetic biology market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129537749?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129537749","market":"us","top_or_hot":-1,"title":"Stock Track | Twist Bioscience Soars 19% on Stellar Q4 Earnings Beat and Upbeat Guidance","media":"Stock Track","content":"<p>Shares of Twist Bioscience (TWST) skyrocketed 19.27% in the pre-market session on Monday, following the company's impressive fiscal fourth quarter 2024 results that surpassed analyst estimates. The synthetic biology company's strong performance was fueled by robust demand for its synthetic DNA products and services across various industries.</p>\n\n<p>For the fourth quarter, Twist Bioscience reported revenue of $84.7 million, a 26.5% increase from the prior year and topping consensus estimates of $82.2 million. The company's net loss narrowed to $0.59 per share, significantly better than the expected loss of $0.71 per share.</p>\n\n<p>Additionally, Twist Bioscience provided an optimistic outlook for fiscal 2025, forecasting full-year revenue between $367 million and $377 million, exceeding analysts' projections of $371.4 million. The company's proprietary DNA synthesis platform continues to gain momentum, positioning Twist Bioscience as a leader in the rapidly growing synthetic biology market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Twist Bioscience Soars 19% on Stellar Q4 Earnings Beat and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Twist Bioscience Soars 19% on Stellar Q4 Earnings Beat and Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-18 22:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Twist Bioscience (TWST) skyrocketed 19.27% in the pre-market session on Monday, following the company's impressive fiscal fourth quarter 2024 results that surpassed analyst estimates. The ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1129537749","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129537749","pubTimestamp":1731940361,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Twist Bioscience  skyrocketed 19.27% in the pre-market session on Monday, following the company's impressive fiscal fourth quarter 2024 results that surpassed analyst estimates. The synthetic biology company's strong performance was fueled by robust demand for its synthetic DNA products and services across various industries.For the fourth quarter, Twist Bioscience reported revenue of $84.7 million, a 26.5% increase from the prior year and topping consensus estimates of $82.2 million. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"股票赛道Twist Bioscience因第四季度盈利出色和乐观指引而飙升19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Shares of Twist Bioscience (TWST) skyrocketed 19.27% in the pre-market session on Monday, following the company's impressive fiscal fourth quarter 2024 results that surpassed analyst estimates. The synthetic biology company's strong performance was fueled by robust demand for its synthetic DNA products and services across various industries.\nFor the fourth quarter, Twist Bioscience reported revenue of $84.7 million, a 26.5% increase from the prior year and topping consensus estimates of $82.2 million. The company's net loss narrowed to $0.59 per share, significantly better than the expected loss of $0.71 per share.\nAdditionally, Twist Bioscience provided an optimistic outlook for fiscal 2025, forecasting full-year revenue between $367 million and $377 million, exceeding analysts' projections of $371.4 million. The company's proprietary DNA synthesis platform continues to gain momentum, positioning Twist Bioscience as a leader in the rapidly growing synthetic biology market.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129537749"}